Want to see CH:YPSN full AI Analyst Report?
YPSN Stock Chart & Stats
CHF307.50
-CHF5.00(-1.41%)
At close: 4:00 PM EST
CHF307.50
-CHF5.00(-1.41%)
Day’s Range― - ―
52-Week RangeCHF260.50 - CHF441.50
Previous CloseN/A
Volume2.70K
Average Volume (3M)17.31K
Market Cap
CHF5.21B
Enterprise ValueCHF4.81B
Total Cash (Recent Filing)CHF28.56M
Total Debt (Recent Filing)CHF260.77M
Price to Earnings (P/E)23.4
Beta0.65
Next Earnings
Nov 11, 2026EPS Estimate
5.25Next Dividend Ex-DateN/A
Dividend Yield1.15%
Share Statistics
EPS (TTM)16.31
Shares Outstanding13,649,739
10 Day Avg. Volume12,508
30 Day Avg. Volume17,306
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)5.02
Price to Sales (P/S)5.14
P/FCF Ratio-229.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF342.00Price Target Upside11.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)13.19
Revenue Forecast (FY)CHF710.32M
Bulls Say, Bears Say
Bulls Say
Profitability & Operating Cash FlowConsistently strong operating cash (>CHF 300m) and a high EBIT margin signal durable internal funding capacity and earnings quality. This supports capex, R&D and shareholder returns while reducing reliance on external financing, improving long‑term resilience and funding optionality.
Deep, Converting Delivery Systems PipelineA large, diversified project pipeline and high historical hit rate provide multi-year revenue visibility for recurring device production. High conversion potential across many clients reduces concentration risk and underpins sustainable device and consumables revenue once programs scale.
Product & Service Innovation (IP + Speed)New recyclable platforms extend IP protection into the 2030s–2040s and strengthen product differentiation. Faster Clear‑to‑Clinic programs materially shorten customer development cycles, increasing win probability and lowering customer switching costs, supporting durable competitive advantage.
Bears Say
Persistent Negative Free Cash FlowDespite strong operating cash, recurring negative free cash flow reflects heavy ongoing investment and working capital use. Persistent FCF deficits constrain financial flexibility, may require external funding or slower buybacks, and limit the pace at which cash returns or expansion can be self‑funded.
Recent Revenue ContractionA drop in reported revenue weakens near‑term top‑line momentum and raises execution risk for medium‑term targets. If project timing, contract phasing or client mix shifts persist, management must convert pipeline and ramp commercial production to restore sustained revenue growth.
Ramp‑up Costs & Phased‑out Contract ManufacturingPlanned phase‑outs reduce near‑term revenue headcount and create temporary top‑line gaps while large footprint projects cause ramp‑up and stranded costs. These execution costs can depress free cash flow and margins in the medium term until new capacity reaches scale.
YPSN FAQ
What was Ypsomed Holding AG’s price range in the past 12 months?
Ypsomed Holding AG lowest stock price was CHF260.50 and its highest was CHF441.50 in the past 12 months.
What is Ypsomed Holding AG’s market cap?
Ypsomed Holding AG’s market cap is CHF5.21B.
When is Ypsomed Holding AG’s upcoming earnings report date?
Ypsomed Holding AG’s upcoming earnings report date is Nov 11, 2026 which is in 108 days.
How were Ypsomed Holding AG’s earnings last quarter?
Ypsomed Holding AG released its earnings results on May 20, 2026. The company reported CHF6.11 earnings per share for the quarter, beating the consensus estimate of CHF6 by CHF0.11.
Is Ypsomed Holding AG overvalued?
According to Wall Street analysts Ypsomed Holding AG’s price is currently Undervalued.
Does Ypsomed Holding AG pay dividends?
Ypsomed Holding AG pays a Annually dividend of CHF4.4 which represents an annual dividend yield of 1.15%. See more information on Ypsomed Holding AG dividends here
What is Ypsomed Holding AG’s EPS estimate?
Ypsomed Holding AG’s EPS estimate is 5.25.
How many shares outstanding does Ypsomed Holding AG have?
Ypsomed Holding AG has 13,649,739 shares outstanding.
What happened to Ypsomed Holding AG’s price movement after its last earnings report?
Ypsomed Holding AG reported an EPS of CHF6.11 in its last earnings report, beating expectations of CHF6. Following the earnings report the stock price went up 9.33%.
Which hedge fund is a major shareholder of Ypsomed Holding AG?
Currently, no hedge funds are holding shares in CH:YPSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ypsomed Holding AG
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
YPSN Stock 12 Month Forecast
Average Price Target
CHF342.00
▲(11.22% Upside)